Improving outcomes of elderly patients with community-acquired pneumonia

Drugs and Aging

Volumn 25, Issue 7, 2008, Pages 585-610

  Gutiérrez, Félix ^a   Masiá, Mar ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

Author keywords

Antibacterials, therapeutic use; Community acquired pneumonia, treatment; Elderly

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; AZTREONAM; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFEPIME; CEFOTAXIME; CEFTRIAXONE; CIPROFLOXACIN; DAPTOMYCIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GEMIFLOXACIN; IMIPENEM; INFLUENZA VACCINE; LEVOFLOXACIN; LINEZOLID; MACROLIDE; MEROPENEM; MOXIFLOXACIN; PIPERACILLIN PLUS TAZOBACTAM; PNEUMOCOCCUS VACCINE; PROTON PUMP INHIBITOR; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TIMENTIN; UNINDEXED DRUG; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ASPIRATION PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CLINICAL PROTOCOL; COMMUNITY ACQUIRED PNEUMONIA; DEMENTIA; DISEASE SEVERITY; DRUG CHOICE; ELDERLY CARE; HUMAN; INFECTION RISK; MICROBIAL IDENTIFICATION; MORTALITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; RESPIRATORY FAILURE; RESPIRATORY VIRUS; REVIEW; SCORING SYSTEM; SEPSIS; SEPTIC SHOCK; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; ANTI-INFECTIVE AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DECISION SUPPORT TECHNIQUES; FRAIL ELDERLY; HUMANS; MICROBIOLOGICAL TECHNIQUES; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PNEUMONIA; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 46349095712     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200825070-00005     Document Type: Review

References (218)

1. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society con sensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007; 44: S27-72
2. Niederman MS, McCombs J, Unger A, et al. The cost of treating community-acquired pneumonia. Clin Ther 1998; 20: 820-36
3. Feikin DR, Schuchat A, Kolczak M, et al. Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997. Am J Public Health 2000; 90: 223-9
4. Gutiérrez F, Masiá M, Mirete C, et al. The influence of age and gender on the population-based incidence of community-acquired pneumonia caused by different microbial pathogens. J Infect 2006; 53: 166-74
5. Jackson ML, Neuzil KM, Thompson WW, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis 2004; 39: 1642-50
6. May DS, Kelly JJ, Mendlein JM, et al. Surveillance of major causes of hospitalization among the elderly, 1988. MMWR Morb Mortal Wkly Rep 1991; 40: 7-21
7. Cunha BA. Pneumonia in the elderly. Clin Microbiol Infect 2001; 7: 581-8
8. Marrie TJ. Community-acquired pneumonia in the elderly. Clin Infect Dis 2000; 31: 1066-78
9. Torres A, El-Ebiary M, Riquelme R, et al. Community-acquired pneumonia in the elderly. Semin Respir Infect 1999; 14: 173-83
10. Neralla S, Meyer KC. Drug treatment of pneumococcal pneumonia in the elderly. Drugs Aging 2004; 21: 851-64
11. Koivula I, Sten M, Makela PH. Risk factors for pneumonia in the elderly. Am J Med 1994; 96: 313-20
12. Farr BM, Woodhead MA, Macfarlane JT, et al. Risk factors for community-acquired pneumonia diagnosed by general practitioners in the community. Respir Med 2000; 94: 422-7
13. Chi RC, Jackson LA, Neuzil KM. Characteristics and outcomes of older adults with community-acquired pneumococcal bacteremia. J Am Geriatr Soc 2006; 54: 115-20
14. Jokinen C, Heiskanen L, Juvonen H, et al. Incidence of community-acquired pneumonia in the population of four municipalities in Eastern Finland. Am J Epidemiol 1993; 137: 977-88
15. National Center for Health Statistics. Health, United States, 2006, with chartbook on trends in the health of Americans. Hyattesville (MD): National Center for Health Statistics, 2006 [online]. Available from URL: http://www.cdc.gov/nchs/data/ hus/hus06.pdf [Accessed 2007 Jun 17]
16. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336: 243-50
17. Fernández-Sabé N, Carratalá J, Rosón B, et al. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics and outcomes. Medicine (Baltimore) 2003; 82: 159-69
18. Kaplan V, Angus DC, Griffin MF, et al. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. Am J Respir Crit Care Med 2002; 165: 766-72
19. Gutiérrez F, Masiá M, Rodriguez JC, et al. Epidemiology of community-acquired pneumonia at the dawn of the twenty first century: a prospective study on the Mediterranean coast of Spain. Clin Microbiol Infect 2005; 11: 788-800
20. Clemente MG, Budino TG, Seco GA, et al. Community-acquired pneumonia in the elderly: prognostic factors [in Spanish]. Arch Bronconeumol 2002; 38: 67-71
21. Garcia-Ordonez MA, Garcia-Jimenez JM, Paez F, et al. Clinical aspects and prognostic factors in elderly patients hospitalised for community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2001; 20: 14-9
22. Riquelme R, Torres A, El-Elbiary M, et al. Community-acquired pneumonia in the elderly: A multivariate analysis of risk and prognostic factors. Am J Respir Crit Care Med 1996; 154: 1450-5
23. Koivula I, Sten M, Makela PH. Prognosis after community-acquired pneumonia in the elderly: a population-based 12-year follow-up study. Arch Intern Med 1999; 59: 1550-5
24. Kaplan V, Clermont G, Griffin MF, et al. Pneumonia: still the old man's friend? Arch Intern Med 2003; 163: 317-23
25. Torres OH, Munoz J, Ruiz D, et al. Outcome predictors of pneumonia in elderly patients: importance of functional assessment. J Am Geriatr Soc 2004; 52: 1603-9
26. Conte HA, Chen YT, Mehal W, et al. A prognostic rule for elderly patients admitted with community-acquired pneumonia. Am J Med 1999; 106: 20-8
27. Ewig S, Kleinfeld T, Bauer T, et al. Comparative validation of prognostic rules for community-acquired pneumonia in an elderly population. Eur Respir J 1999; 14: 370-5
28. Lim WS, Macfarlane JT. Defining prognostic factors in the elderly with community-acquired pneumonia: a case controlled study of patients aged ≥75 yrs. Eur Respir J 2001; 17: 200-5
29. Rello J, Rodriguez R, Jubert P, et al., and the Study Group for Severe Community-acquired Pneumonia. Severe community-acquired pneumonia in the elderly: epidemiology and prognosis. Clin Infect Dis 1996; 23: 723-8
30. Niederman MS. Recent advances in community-acquired pneumonia: inpatient and outpatient. Chest 2007; 131: 1205-15
31. Dean NC, Bateman KA, Donnelly SM, et al. Improved clinical outcomes with utilization of a community-acquired pneumonia guideline. Chest 2006 Sep; 130 (3): 794-9
32. Dean NC, Silver MP, Bateman KA, et al. Decreased mortality after implementation of a treatment guideline for community-acquired pneumonia. Am J Med 2001; 110: 451-7
33. Marrie TJ, Lau CY, Wheeler SL, et al. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators: Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin. JAMA 2000; 283: 749-55
34. Capelastegui A, Espana PP, Quintana JM, et al. Improvement of process-of-care and outcomes after implementing a guideline for the management of community-acquired pneumonia: a controlled before-and-after design study. Clin Infect Dis 2004; 39: 955-63
35. Mortensen EM, Restrepo M, Anzueto A, et al. Effects of guideline concordant antimicrobial therapy on mortality among patients with community-acquired pneumonia. Am J Med 2004; 117: 726-31
36. Meehan TP, Weingarten SR, Holmboe ES, et al. A statewide initiative to improve the care of hospitalized pneumonia patients: the Connecticut Pneumonia Pathway Project. Am J Med 2001; 111: 203-10
37. Kollef MH, Shorr A, Tabak YP, et al. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. Chest 2005; 128: 3854-62
38. Niederman MS, Craven DE, Bonten MJ, et al. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171: 388-416
39. Hiramatsu K, Niederman MS. Health-care-associated pneumonia: a new therapeutic paradigm. Chest 2005; 128: 3784-7
40. Mylotte JM. Nursing home-acquired pneumonia: update on treatment options. Drugs Aging 2006; 23: 377-90
41. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax 2003; 58: 377-82
42. Juthani-Mehta M, Quagliarello V. Prognostic scoring systems for infectious diseases: their applicability to the care of older adults. Clin Infect Dis 2004; 38: 692-6
43. Masiá M, Gutiérrez F, Shum C, et al. Usefulness of pro-calcitonin levels in community-acquired pneumonia according to the patient's outcome research team pneumonia severity index. Chest 2005; 128: 2223-9
44. Mirete C, Gutiérrez F, Masiá M, et al. Usefulness of acute-phase proteins in community-acquired pneumonia [in Spanish]. Med Clin (Barc) 2004; 122: 245-7
45. Masiá M, Gutiérrez F, Llorca B, et al. Serum concentrations of lipopolysaccharide-binding protein as a biochemical marker to differentiate microbial etiology in patients with community-acquired pneumonia. Clin Chem 2004; 50: 1661-4
46. Christ-Crain M, Stolz D, Bingisser R, et al. Procalcitonin-guidance of antibiotic therapy in community-acquired pneumonia: a randomized trial. Am J Respir Crit Care Med 2006; 174: 84-93
47. Hedlund J, Hansson LO. Procalcitonin and C-reactive protein levels in community-acquired pneumonia: correlation with etiology and prognosis. Infection 2000; 28: 68-73
48. Brunkhorst FM, Al-Nawas B, Krummenauer F, et al. Pro-calcitonin, C-reactive protein and APACHE II score for risk evaluation in patients with severe pneumonia. Clin Microbiol Infect 2002; 8: 93-100
49. Mueller C, Laule-Kilian K, Scholer A, et al. B-type natriuretic peptide for risk stratification in community-acquired pneumonia. J Intern Med 2005: 258; 391-3
50. Christ-Crain M, Morgenthaler NG, Stolz D, et al. Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]. Crit Care 2006; 10: R96
51. Masiá M, Papassotiriou J, Morgenthaler N, et al. Midregional pro-A-type natriuretic peptide and carboxy-terminal provasopressin may predict prognosis in community-acquired pneumonia. Clin Chem 2007 Dec; 53 (12): 2193-201
52. Suchyta MR, Dean NC, Narus S, et al. Effects of a practice guideline for community-acquired pneumonia in an outpatient setting. Am J Med 2001; 110: 306-9
53. Arnold FW, Ramirez JA, McDonald LC, et al. Hospitalization for community-acquired pneumonia: the pneumonia severity index vs clinical judgment. Chest 2003; 124: 121-4
54. Goss CH, Rubenfeld GD, Park DR, et al. Cost and incidence of social comorbidities in low-risk patients with community-acquired pneumonia admitted to a public hospital. Chest 2003; 124: 2148-55
55. Auble TE, Yealy DM, Fine MJ. Assessing prognosis and selecting an initial site of care for adults with community-acquired pneumonia. Infect Dis Clin North Am 1998; 12: 741-59
56. Riley PD, Aronsky D, Dean NC. Validation of the 2001 American Thoracic Society criteria for severe community-acquired pneumonia. Crit Care Med 2004; 32: 2398-402
57. Angus DC, Marrie TJ, Obrosky DS, et al. Severe community-acquired pneumonia: use of intensive care services and evaluation of American and British Thoracic Society diagnostic criteria. Am J Respir Crit Care Med 2002; 166: 717-23
58. Roson B, Carratala J, Dorca J, et al. Etiology, reasons for hospitalization, risk classes, and outcomes of community-acquired pneumonia in patients hospitalized on the basis of conventional admission criteria. Clin Infect Dis 2001; 33: 158-65
59. El Solh AA, Sikka P, Ramadan F, et al. Etiology of severe pneumonia in the very elderly. Am J Respir Crit Care Med 2001; 163: 645-51
60. Luna CM, Famiglietti A, Absi R, et al. Community-acquired pneumonia: etiology, epidemiology, and outcome at a teaching hospital in Argentina. Chest 2000; 118: 1344-54
61. Meehan TP, Chua-Reyes JM, Tate J, et al. Process of care performance, patient characteristics, and outcomes in elderly patients hospitalized with community-acquired or nursing home-acquired pneumonia. Chest 2000; 117: 1378-85
62. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia: diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163: 1730-54
63. Ely EW, Evans GW, Haponik EF. Mechanical ventilation in a cohort of elderly patients admitted to an intensive care unit. Ann Intern Med 1999; 131: 96-104
64. Metlay JP, Schulz R, Li YH, et al. Influence of age on symptoms at presentation in patients with community-acquired pneumonia. Arch Intern Med 1997; 157: 1453-9
65. Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis 1998; 27: 358-63
66. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Comparison between pathogen directed antibiotic treatment and empirical broad spectrum antibiotic treatment in patients with community acquired pneumonia: a prospective randomised study. Thorax 2005; 60: 672-8
67. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51: 179-84
68. Gutiérrez F, Masiá M, Rodriguez JC, et al. Community-acquired pneumonia of mixed etiology: prevalence, clinical characteristics, and outcome. Eur J Clin Microbiol Infect Dis 2005; 24: 377-83
69. Martínez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36: 396-8
70. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161: 1837-42
71. Musher DM, Montoya R, Wanahita A. Diagnostic value of microscopic examination of Gram-stained sputum and sputum cultures in patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2004; 39: 165-9
72. Lentino JR, Lucks DA. Nonvalue of sputum culture in the management of lower respiratory tract infections. J Clin Microbiol 1987; 25: 758-62
73. Roson B, Carratala J, Verdaguer R, et al. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization. Clin Infect Dis 2000; 31: 869-74
74. Gleckman R, DeVita J, Hibert D, et al. Sputum gram stain assessment in community-acquired bacteremic pneumonia. J Clin Microbiol 1988; 26: 846-9
75. Garcia-Vazquez E, Marcos MA, Mensa J, et al. Assessment of the usefulness of sputum culture for diagnosis of community-acquired pneumonia using the PORT predictive scoring system. Arch Intern Med 2004; 164: 1807-11
76. Reed WW, Byrd GS, Gates Jr RH, et al. Sputum gram's stain in community-acquired pneumococcal pneumonia: a meta-analysis. West J Med 1996; 165: 197-204
77. Thorsteinsson SB, Musher DM, Fagan T. The diagnostic value of sputum cultures in acute pneumonia. JAMA 1975; 233: 894-5
78. Gutiérrez F, Masiá M, Rodríguez JC, et al. Evaluation of the immunochromatographic Binax NOW assay for detection of Streptococcus pneumoniae urinary antigen in a prospective study of community-acquired pneumonia in Spain. Clin Infect Dis 2003; 36: 286-92
79. Murdoch DR, Laing RT, Mills GD, et al. Evaluation of a rapid immunochromatographic test for detection of Streptococcus pneumoniae antigen in urine samples from adults with community-acquired pneumonia. J Clin Microbiol 2001; 39: 3495-8
80. Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial Legionnaires' disease. J Clin Microbiol 2003; 41: 838-40
81. Rosón B, Fernández-Sabe N, Carratalá J, et al. Contribution of a urinary antigen assay (Binax NOW) to the early diagnosis of pneumococcal pneumonia. Clin Infect Dis 2004; 38: 222-6
82. Murdoch DR. Diagnosis of Legionella infection. Clin Infect Dis 2003; 36: 64-9
83. Helbig JH, Uldum SA, Luck PC, et al. Detection of Legionella pneumophila antigen in urine samples by the Binax NOW immunochromatographic assay and comparison with both Binax Legionella Urinary Enzyme Immunoassay (EIA) and Biotest Legionella Urin Antigen EIA. J Med Microbiol 2001; 50: 509-16
84. Yzerman EP, den Boer JW, Lettinga KD, et al. Sensitivity of three urinary antigen tests associated with clinical severity in a large outbreak of Legionnaires' disease in the Netherlands. J Clin Microbiol 2002; 40: 3232-6
85. Mirete C, Gutiérrez F, Rodriguez JC, et al. Etiology of community-acquired pneumonia in ambulatory patients: usefulness of a diagnostic investigation protocol using detection of Streptococcus pneumoniae and Legionella pneumophila antigens in urine samples. Med Clin (Barc) 2001; 117: 657-9
86. Bellei N, Benfica D, Perosa AH, et al. Evaluation of a rapid test (QuickVue) compared with the shell vial assay for detection of influenza virus clearance after antiviral treatment. J Virol Methods 2003; 109: 85-8
87. Dominguez J, Gali N, Blanco S, et al. Detection of Streptococcus pneumoniae antigen by a rapid immunochromatographic assay in urine samples. Chest 2001; 119: 243-9
88. Rodriguez JC, Masiá M, Gutiérrez F, et al. Legionella pneumophila in community acquired pneumonia: interpretation of microbiological techniques [in Spanish]. Med Clin (Barc) 2004; 122: 277-8
89. den Boer JW, Yzerman EP, Schellekens J, et al. A large outbreak of Legionnaires' disease at a flower show, the Netherlands, 1999. Emerg Infect Dis 2002; 8: 37-43
90. Garcia-Fulgueiras A, Navarro C, Fenoll D, et al. Legionnaires' disease outbreak in Murcia, Spain. Emerg Infect Dis 2003; 9: 915-21
91. Benkel DH, McClure EM, Woolard D, et al. Outbreak of Legionnaires' disease associated with a display whirlpool spa. Int J Epidemiol 2000; 29: 1092-8
92. Kaiser L, Briones MS, Hayden FG. Performance of virus isolation and Directigen Flu A to detect influenza A virus in experimental human infection. J Clin Virol 1999; 14: 191-7
93. Monto AS, Gravenstein S, Elliott M, et al. Clinical signs and symptoms predicting influenza infection. Arch Intern Med 2000; 160: 3243-7
94. Campbell SG, Marrie TJ, Anstey R, et al. The contribution of blood cultures to the clinical management of adult patients admitted to the hospital with community-acquired pneumonia: a prospective observational study. Chest 2003; 123: 1142-50
95. Waterer GW, Wunderink RG. The influence of the severity of community-acquired pneumonia on the usefulness of blood cultures. Respir Med 2001; 95: 78-82
96. Houck PM, Bratzler DW, Nsa W, et al. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004; 164: 637-44
97. Yu VL, Chiou CC, Feldman C, et al. An international prospective study of pneumococcal bacteremia: correlation with in vitro resistance, antibiotics administered, and clinical outcome. Clin Infect Dis 2003; 37: 230-7
98. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74
99. Marik PE. The clinical features of severe community-acquired pneumonia presenting as septic shock. Norasept II Study Investigators. J Crit Care 2000; 15: 85-90
100. Ruiz M, Ewig S, Torres A, et al. Severe community-acquired pneumonia. Am J Respir Crit Care Med 1999; 160: 923-9
101. Paganin F, Lilienthal F, Bourdin A, et al. Severe community-acquired pneumonia: assessment of microbial aetiology as mortality factor. Eur Respir J 2004; 24: 779-85
102. Metersky ML, Ma A, Bratzler DW, et al. Predicting bacteremia in patients with community-acquired pneumonia. Am J Respir Crit Care Med 2004; 169: 342-7
103. Ruiz M, Ewig S, Marcos MA, et al. Etiology of community-acquired pneumonia: impact of age, comorbidity, and severity. Am J Respir Crit Care Med 1999; 160: 397-405
104. Confalonieri M, Potena A, Carbone G, et al. Acute respiratory failure in patients with severe community-acquired pneumonia: a prospective randomized evaluation of non-invasive ventilation. Am J Respir Crit Care Med 1999; 160: 1585-91
105. Dowell SF, Peeling RW, Boman J, et al. Standardizing Chlamydia pneumoniae assays: recommendations from the Centers for Disease Control and Prevention (USA) and the Laboratory Centre for Disease Control (Canada). Clin Infect Dis 2001; 33: 492-503
106. Templeton KE, Scheltinga SA, van den Eeden WC, et al. Improved diagnosis of the etiology of community-acquired pneumonia with real-time polymerase chain reaction. Clin Infect Dis 2005; 41: 345-51
107. Bartlett JG. Diagnostic test for etiologic agents of community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 809-27
108. Jimenez P, Saldias F, Meneses M, et al. Diagnostic fiberoptic bronchoscopy in patients with community-acquired pneumonia: comparison between bronchoalveolar lavage and telescoping plugged catheter cultures. Chest 1993; 103: 1023-7
109. Zalacain R, Llorente JL, Gaztelurrutia L, et al. Influence of three factors on the diagnostic effectiveness of transthoracic needle aspiration in pneumonia. Chest 1995; 107: 96-100
110. Scott JA, Hall AJ. The value and complications of percutaneous transthoracic lung aspiration for the etiologic diagnosis of community-acquired pneumonia. Chest 1999; 116: 1716-32
111. Ishida T, Hashimoto T, Arita M, et al. Efficacy of transthoracic needle aspiration in community-acquired pneumonia. Intern Med 2001; 40: 873-7
112. Arancibia F, Ewig S, Martinez JA, et al. Antimicrobial treatment failures in patients with community-acquired pneumonia: causes and prognostic implications. Am J Respir Crit Care Med 2000; 162: 154-60
113. van der Eerden MM, Vlaspolder F, de Graaff CS, et al. Value of intensive diagnostic microbiological investigation in low- and high-risk patients with community-acquired pneumonia. Eur J Clin Microbiol Infect Dis 2005; 24: 241-9
114. Wimberley N, Faling LJ, Bartlett JG. A fiberoptic bronchoscopy technique to obtain uncontaminated lower airway secretions for bacterial culture. Am Rev Respir Dis 1979; 119: 337-43
115. Bartlett JG. Diagnosis of bacterial infections of the lung. Clin Chest Med 1987; 8: 119-34
116. Meehan TP, Fine MJ, Krumholz HM, et al. Quality of care, process, and outcomes in elderly patients with pneumonia. JAMA 1997; 278: 2080-4
117. Benenson R, Magalski A, Cavanaugh S, et al. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad Emerg Med 1999; 6: 1243-8
118. Marrie TJ, Wu L. Factors influencing in-hospital mortality in community-acquired pneumonia: a prospective study of patients not initially admitted to the ICU. Chest 2005; 127: 1260-70
119. Kauppinen MT, Herva E, Kujala P, et al. The etiology of community-acquired pneumonia among hospitalized patients during a Chlamydia pneumoniae epidemic in Finland. J Infect Dis 1995; 172: 1330-5
120. Woodhead M. Pneumonia in the elderly. J Antimicrob Chemother 1994; 34 Suppl. 34: 85-92
121. Falguera M, Sacristan O, Nogues A, et al. Nonsevere community acquired pneumonia: correlation between cause and severity or comorbidity. Arch Intern Med 2001; 161: 1866-72
122. Alvarez FJ, García A, Elias T, et al. Community acquired pneumonia in patients older than 60 years. Incidence of atypical agents and clinical-radiological progression. Med Clin (Barc) 2001; 117: 441-5
123. Masiá M, Gutiérrez F, Padilla S, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect 2007; 13 (2): 153-61
124. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162: 1849-58
125. File TM. Community-acquired pneumonia. Lancet 2003; 362: 1991-2001
126. Mirete JC, Gutiérrez F, Hernandez I, et al. Community-acquired pneumonia associated with influenza virus. Med Clin (Barc) 2002; 118: 622-6
127. Diaz A, Barria P, Niederman M, et al. Etiology of community-acquired pneumonia in hospitalized patients in Chile: the increasing prevalence of respiratory viruses among classic pathogens. Chest 2007; 131: 779-87
128. Falsey AR, Walsh EE. Viral pneumonia in older adults. Clin Infect Dis 2006; 42: 518-24
129. Falsey AR, Hennessey PA, Formica MA, et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 2005; 352: 1749-59
130. Kikuchi R, Watabe N, Konno T, et al. High incidence of silent aspiration in elderly patients with community-acquired pneumonia. Am J Respir Crit Care Med 1994; 150: 251-3
131. Fu C, Chute DJ, Farag ES, et al. Comorbidity in dementia: an autopsy study. Arch Pathol Lab Med 2004; 128: 32-8
132. Loeb M, McGeer A, McArthur M, et al. Risk factors for pneumonia and other respiratory tract infections in elderly residents of long-term care facilities. Arch Intern Med 1999; 159: 2058-64
133. Vergis EN, Brennen C, Wagener M, et al. Pneumonia in long-term care: a prospective case-control study of risk factors and impact on survival. Arch Intern Med 2001; 161: 2378-81
134. Malik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med 2001; 344: 665-71
135. Morice AH, Lowry R, Brown MJ, et al. Angiotensin-converting enzyme and the cough reflex. Lancet 1987; 2: 1116-8
136. Sekizawa K, Matsui T, Nakagawa T, et al. ACE inhibitors and pneumonia [letter]. Lancet 1998; 352: 1069
137. Arai T, Yasuda Y, Toshima S, et al. ACE inhibitors and pneumonia in elderly people [letter]. Lancet 1998; 352: 1937-8
138. van de Garde EM, Souverein PC, van den Bosch JM, et al. Angiotensin-converting enzyme inhibitor use and pneumonia risk in a general population. Eur Respir J 2006; 27: 1217-22
139. Teramoto S, Ouchi Y. ACE inhibitors and prevention of aspiration pneumonia in elderly hypertensives [letter]. Lancet 1999; 353: 843
140. Ohkubo T, Chapman N, Neal B, et al. Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Perindopril Protection Against Recurrent Stroke Study Collaborative Group. Am J Respir Crit Care Med 2004; 169: 1041-5
141. Gulmez SE, Holm A, Frederiksen H, et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007; 167: 950-5
142. Torres A, Serra-Batlles J, Ferrer A, et al. Severe community-acquired pneumonia: epidemiology and prognostic factors. Am Rev Respir Dis 1991; 144: 312-8
143. Waterer GW, Buckingham SC, Kessler LA, et al. Decreasing β-lactam resistance in pneumococci from the Memphis region: analysis of 2,152 isolates from 1996 to 2001. Chest 2003; 124: 519-25
144. Perez-Trallero E, Garcia-de-la-Fuente C, Garcia-Rey C, et al. Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72
145. Metlay JP. Antibacterial drug resistance: implications for the treatment of patients with community-acquired pneumonia. Infect Dis Clin North Am 2004; 18: 777-90
146. Bauer T, Ewig S, Marcos MA, et al. Streptococcus pneumoniae in community-acquired pneumonia: how important is drug resistance? Med Clin North Am 2001; 85: 1367-79
147. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community- acquired pneumonia in the era of pneumococcal resistance: a report from the Drug-Resistant Streptococcus pneumoniae Therapeutic Working Group. Arch Intern Med 2000; 160: 1399-408
148. Pallares R, Capdevila O, Linares J, et al. The effect of cephalosporin resistance on mortality in adult patients with nonmeningeal systemic pneumococcal infections. Am J Med 2002; 113: 120-6
149. Musher DM, Dowell ME, Shortridge VD, et al. Emergence of macrolide resistance during treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 630-1
150. Kelley MA, Weber DJ, Gilligan P, et al. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11
151. Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 35: 556-64
152. Chen DK, McGeer A, de Azavedo JC, et al. Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada: Canadian Bacterial Surveillance Network. N Engl J Med 1999; 341: 233-9
153. Davidson R, Cavalcanti R, Brunton JL, et al. Resistance to levofloxacin and failure of treatment of pneumococcal pneumonia. N Engl J Med 2002; 346: 747-50
154. Ho PL, Yung RW, Tsang DN, et al. Increasing resistance of Streptococcus pneumoniae to fluoroquinolones: results of a Hong Kong multicentre study in 2000. J Antimicrob Chemother 2001; 48: 659-65
155. Gorak EJ, Yamada SM, Brown JD. Community-acquired methicillin resistant Staphylococcus aureus in hospitalized adults and children without known risk factors. Clin Infect Dis 1999; 29: 797-800
156. Dufour P, Gillet Y, Bes M, et al. Community-acquired methicillin- resistant Staphylococcus aureus infections in France: emergence of a single clone that produces Panton-Valentine leukocidin. Clin Infect Dis 2002; 35: 819-24
157. Mongkolrattanothai K, Boyle S, Kahana MD, et al. Severe Staphylococcus aureus infections caused by clonally related community-acquired methicillin-susceptible and methicillin-resistant isolates. Clin Infect Dis 2003; 37: 1050-8
158. Deresinski S. Methicillin-resistant Staphylococcus aureus: an evolutionary, epidemiologic, and therapeutic odyssey. Clin Infect Dis 2005; 40: 562-73
159. Fridkin SK, Hageman JC, Morrison M, et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005; 352: 1436-44
160. Micek ST, Dunne M, Kollef MH. Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production. Chest 2005; 128: 2732-8
161. Vanderkooi OG, Low DE, Green K, et al. Predicting antimicrobial resistance in invasive pneumococcal infections. Clin Infect Dis 2005; 40: 1288-97
162. Kaiser L, Keene ON, Hammond JM, et al. Impact of zanamivir on antibiotic use for respiratory events following acute influenza in adolescents and adults. Arch Intern Med 2000; 160: 3234-40
163. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA 2000; 283: 1016-24
164. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA 1999; 282: 1240-6
165. Hyde TB, Gay K, Stephens DS, et al. Macrolide resistance among invasive Streptococcus pneumoniae isolates. JAMA 2001; 286: 1857-62
166. Clavo-Sanchez AJ, Giron-Gonzalez JA, Lopez-Prieto D, et al. Multivariate analysis of risk factors for infection due to penicillin-resistant and multidrug-resistant Streptococcus pneumoniae: a multicenter study. Clin Infect Dis 1997; 24: 1052-9
167. Ho PL, Tse WS, Tsang KW, et al. Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study. Clin Infect Dis 2001; 32: 701-7
168. Ruhe JJ, Hasbun R. Streptococcus pneumoniae bacteremia: duration of previous antibiotic use and association with penicillin resistance. Clin Infect Dis 2003; 36: 1132-8
169. Anderson KB, Tan JS, File Jr TM, et al. Emergence of levofloxacin- resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia. Clin Infect Dis 2003; 37: 376-81
170. Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-52
171. Goldstein EJ, Citron DM, Warren YA, et al. In vitro activity of moxifloxacin against 923 anaerobes isolated from human intra-abdominal infections. Antimicrob Agents Chemother 2006; 50: 148-55
172. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107 (1A): 34S-43S
173. Baddour LM, Yu VL, Klugman KP, et al. Combination antibiotic therapy
174. Weiss K, Low DE, Cortes L, et al. Clinical characteristics at initial presentation and impact of dual therapy on the outcome of bacteremic Streptococcus pneumoniae pneumonia in adults. Can Respir J 2004; 11: 589-93
175. Dudas V, Hopefl A, Jacobs R, et al. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34: 446-52
176. Houck PM, MacLehose RF, Niederman MS, et al. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 western states: 1993, 1995, and 1997. Chest 2001; 119: 1420-6
177. Stahl JE, Barza M, DesJardin J, et al. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159: 2576-80
178. Brown RB, Iannini P, Gross P, et al. Impact of initial antibiotic choice on clinical outcomes in community-acquired pneumonia: analysis of a hospital claims-made database. Chest 2003; 123: 1503-11
179. Gleason PP, Meehan TP, Fine JM, et al. Association between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159: 2562-72
180. Anzueto A, Niederman MS, Pearle J, et al. Community-Acquired Pneumonia Recovery in the Elderly (CAPRIE): efficacy and safety of moxifloxacin therapy versus that of levofloxacin therapy. Clin Infect Dis 2006; 42: 73-81
181. Shorr AF, Zadeikis N, Xiang JX, et al. A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged ≥65 years with community-acquired pneumonia. Clin Ther 2005; 27: 1251-9
182. Leroy O, Saux P, Bedos JP, et al. Comparison of levofloxacin and cefotaxime combined with ofloxacin for ICU patients with community-acquired pneumonia who do not require vasopressors. Chest 2005; 128: 172-83
183. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease. N Engl J Med 1995; 333: 817-22
184. Ferrer M, Esquinas A, Leon M, et al. Noninvasive ventilation in severe hypoxemic respiratory failure: a randomized clinical trial. Am J Respir Crit Care Med 2003; 168: 1438-44
185. Bernard GR, Vincent JL, Laterre PF, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344: 699-709
186. Ely EW, Laterre PF, Angus DC, et al. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Crit Care Med 2003; 31: 12-9
187. Ely EW, Angus DC, Williams MD, et al. Treatment of older patients with severe sepsis using drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 187-95
188. Laterre PF, Garber G, Levy H, et al. Severe community-acquired pneumonia as a cause of severe sepsis: data from the PROWESS study. Crit Care Med 2005; 33: 952-61
189. Opal SM, Garber GE, LaRosa SP, et al. Systemic host responses in severe sepsis analyzed by causative microorganism and treatment effects of drotrecogin alfa (activated). Clin Infect Dis 2003; 37: 50-8
190. Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA 2002; 288: 862-71
191. Alikhan R, Cohen AT, Combe S, et al. Risk factors for venous thromboembolism in hospitalized patients with acute medical illness: analysis of the MEDENOX study. Arch Intern Med 2004; 164: 963-8
192. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients: Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793-800
193. Leizorovicz A, Cohen AT, Turpie AG, et al. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation 2004; 110: 874-9
194. Cohen AT, Gallus AS, Lassen MR, et al. Fondaparinux vs. placebo for the prevention of venous thromboembolism in acutely ill medical patients (ARTEMIS) [abstract]. J Thromb Haemost 2003; 1 Suppl.: 2046
195. Wenger NK. Early ambulation after myocardial infarction: the in-patient exercise program. Clin Sports Med 1984; 3: 333-48
196. Munin MC. Early inpatient rehabilitation after elective hip and knee arthroplasty. JAMA 1998; 279: 847-52
197. Mundy LM, Leet TL, Darst K, et al. Early mobilization of patients hospitalized with community-acquired pneumonia. Chest 2003; 124: 883-9
198. Halm EA, Fine MJ, Marrie TJ, et al. Time to clinical stability in patients hospitalized with community-acquired pneumonia. JAMA 1998; 279: 1452-7
199. Rhew DC, Riedinger MS, Sandhu M, et al. A prospective, multicenter study of a pneumonia practice guideline. Chest 1998; 114: 115-9
200. Ramirez JA, Vargas S, Ritter GW, et al. Early switch from intravenous to oral antibiotics and early hospital discharge: a prospective observational study of 200 consecutive patients with community-acquired pneumonia. Arch Intern Med 1999; 159: 2449-54
201. Halm EA, Switzer GE, Mittman BS, et al. What factors influence physicians' decisions to switch from intravenous to oral antibiotics for community-acquired pneumonia? J Gen Intern Med 2001; 16: 599-605
202. Halm EA, Fine MJ, Kapoor WN, et al. Instability on hospital discharge and the risk of adverse outcomes in patients with pneumonia. Arch Intern Med 2002; 162: 1278-84
203. Menéndez R, Torres A, Rodriguez de Castro F, et al. Reaching stability in community-acquired pneumonia: the effects of the severity of disease, treatment, and the characteristics of patients. Clin Infect Dis 2004; 39: 1783-90
204. Ramirez JA, Srinath L, Ahkee S, et al. Early switch from intravenous to oral cephalosporins in the treatment of hospitalized patients with community-acquired pneumonia. Arch Intern Med 1995; 155: 1273-6
205. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37: 752-60
206. Rubins JB, Alter M, Loch J, et al. Determination of antibody responses of elderly adults to all 23 capsular polysaccharides after pneumococcal vaccination. Infect Immun 1999; 67: 5979-84
207. Jackson LA, Neuzil KM, Yu O, et al. Effectiveness of pneumococcal polysaccharide vaccine in older adults. N Engl J Med 2003; 348: 1747-55
208. Ortqvist A, Hedlund J, Burman LA, et al. Randomised trial of 23-valent pneumococcal capsular polysaccharide vaccine in prevention of pneumonia in middle-aged and elderly people: Swedish Pneumococcal Vaccination Study Group. Lancet 1998; 351: 399-403
209. Vila-Corcoles A, Ochoa-Gondar O, Hospital I, et al. Protective effects of the 23-valent pneumococcal polysaccharide vaccine in the elderly population: the EVAN-65 study. Clin Infect Dis 2006; 43: 860-8
210. Voordouw BC, van der Linden PD, Simonian S, et al. Influenza vaccination in community-dwelling elderly: impact on mortality and influenza-associated morbidity. Arch Intern Med 2003; 163: 1089-94
211. Ortqvist A, Granath F, Askling J, et al. Influenza vaccination and mortality: prospective cohort study of the elderly in a large geographical area. Eur Respir J 2007; 30: 414-22
212. Nichol KL, Nordin J, Mullooly J, et al. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med 2003; 348: 1322-32
213. Voordouw BC, Sturkenboom MC, Dieleman JP, et al. Annual influenza vaccination in community-dwelling elderly individuals and the risk of lower respiratory tract infections or pneumonia. Arch Intern Med 2006; 166: 1980-5
214. Christenson B, Hedlund J, Lundbergh P, et al. Additive preventive effect of influenza and pneumococcal vaccines in elderly persons. Eur Respir J 2004; 23: 363-8
215. Nathwani D, Rubinstein E, Barlow G, et al. Do guidelines for community-acquired pneumonia improve the cost-effectiveness of hospital care? Clin Infect Dis 2001; 32: 728-41
216. Atlas SJ, Benzer TI, Borowsky LH, et al. Safely increasing the proportion of patients with community-acquired pneumonia treated as outpatients: an interventional trial. Arch Intern Med 1998; 158: 1350-6
217. Fine MJ, Stone RA, Lave JR, et al. Implementation of an evidence-based guideline to reduce duration of intravenous antibiotic therapy and length of stay for patients hospitalized with community-acquired pneumonia: a randomized controlled trial. Am J Med 2003; 115: 343-51
218. Chu LA, Bratzler DW, Lewis RJ, et al. Improving the quality of care for patients with pneumonia in very small hospitals. Arch Intern Med 2003; 163: 326-32